Whalesbook
PI Industries ne Q4 mein thoda struggle kiya hai, company ka revenue pichle saal ke mukable 12% kam ho gaya.
CSM Business Mein Badi Giraavat
Is decline ka sabse bada reason raha Custom Synthesis Manufacturing (CSM) business, jisme 15% ki kami aayi hai. Global economic slowdown aur customers ki taraf se order volume kam karne ki wajah se CSM volumes mein 14% ki giravat dekhi gayi.
Domestic Agri Aur Pharma Ka Kya Haal?
Desi Agri-chemical business mein bhi 9% ki revenue kami hui. Haan, pharma business ne accha perform kiya aur 23% grow kiya.
Company ke gross margins 280 basis points improve hue hain, operational efficiencies ki wajah se. Lekin overall volumes kam hone ke karan EBITDA margins 400 basis points gir gaye.
Motilal Oswal Ko Future Pe Bharosa
Kamzor results ke bawajood, Motilal Oswal ne FY27 aur FY28 ke liye earnings forecast badla nahi hai. Unhone PI Industries ke liye apni 'Buy' rating aur ₹3,500 ka target price maintain kiya hai. Ye valuation FY28 earnings ke 33 times P/E multiple par based hai, jo company ke average 37 times P/E se thoda kam hai.
Motilal Oswal ko FY27 mein PI Industries se acche performance ki ummeed hai. Unka positive outlook strong order book, confirmed customer commitments, aur CSM segment mein 5 se zyada naye molecules launch karne ki plans par depend karta hai. Ye naye products FY27 ke second half mein growth ko accelerate kar sakte hain. Iske alawa, company ka Biologicals pipeline aur potential acquisitions bhi future growth ke liye important factors hain.